https://treatcancer.com/wp-content/uploads/2018/01/FullSizeRender2260.jpg 480 640 Lianna Palkovick https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Lianna Palkovick2018-01-03 18:37:222018-01-03 18:39:14Dr. Heinzerling Presents His Research at the OncLive State of the Science Summit
Dr. Heinzerling Presents His Research at the OncLive State of the Science Summit Written by: SERO Staff Dr. Heinzerling presented on the topic of Advanced Non-Small Cell Lung Cancer at the OncLive…
https://treatcancer.com/wp-content/uploads/2017/07/Dr-Corso-photo.jpg 622 600 Lianna Palkovick https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Lianna Palkovick2017-09-10 23:27:512017-09-10 23:33:27Christopher Corso, MD, Ph.D Receives 2017 Basic/Translational Science Abstract Award
Christopher Corso, MD, Ph.D Receives 2017 Basic/Translational Science Abstract Award Written by: SERO Staff The Basic/Translational Science Abstract Award recognizes the lead authors of 12 top-rated…
https://treatcancer.com/wp-content/uploads/2016/01/EbolaVirus.jpg 1920 2560 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-12-30 21:55:252016-01-06 22:11:10Scientists use Lassa-VSV, a combination of deadly viruses, to fight brain tumors
Scientists looking for new treatments for patients with brain tumors, including those caused by metastatic melanoma, have turned to an unlikely source: a deadly tropical virus. The virus, called Lassa, causes a deadly hemorrhagic fever endemic to West Africa. A team of cancer scientists from Yale and Harvard are altering part of the virus's genetic code, combining it with a different virus, and injecting it into the human brain where they hope it can be used to find and destroy cancer cells.
https://treatcancer.com/wp-content/uploads/2016/01/mortar-and-pestle.jpeg 282 425 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-12-24 19:53:272016-01-06 22:13:30New cancer drug binimetinib shows success in late stage trial
On December 16, Array BioPharma announced its new cancer drug, binimetinib, showed success in stage 3 clinical trials. According to the drug company, binimetinib may be used to treat people with advanced NRAS-mutant melanoma, a particularly deadly form of skin cancer. The trial showed that the drug extended the time it takes for cancer to grow and spread.
https://treatcancer.com/wp-content/uploads/2016/01/tanningbed.jpg 672 801 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-12-20 18:26:122016-01-06 22:14:46FDA proposes ban on indoor tanning for minors
Indoor tanning ban aimed at reducing skin cancer rates in minors. On December 18, in a sweeping move in the fight against skin cancer, the FDA proposed a national ban on indoor tanning for people under the age of 18. Medical experts have called the move an important step in reducing the risk of skin cancer in the United States.
https://treatcancer.com/wp-content/uploads/2015/12/Kaposi_sarcoma_high_mag.jpg 2848 4272 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-12-09 00:10:542015-12-16 00:51:18Treatment of Kaposi Sarcoma
A handful of different treatment options are available for patients with Kaposi sarcoma. Treatment options are largely determined by the type of Kaposi sarcoma, the overall health of the patient, and whether the disease is being diagnosed for the first time or if it has come back after initial treatments.
https://treatcancer.com/wp-content/uploads/2015/12/Kaposis_Sarcoma_Lesions.jpg 675 1012 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-12-05 23:48:272015-12-16 00:09:40What is Kaposi Sarcoma?
Kaposi sarcoma is rare type of cancer that causes tumors to form in the skin; mucous membranes lining the mouth, nose, and throat; lymph nodes; or other organs. Tumors caused by Kaposi sarcoma are usually purple and are made of cancer cells, new blood vessels, red blood cells, and white blood cells. Most cancers begin in one part of the body and spread to others; in the case Kaposi sarcoma, lesions may begin in more than one place in the body at the same time.
https://treatcancer.com/wp-content/uploads/2015/12/Gray602.png 505 500 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-12-01 23:29:522015-12-15 23:41:53Skin Lymphoma
Skin lymphoma is a rare type of cancer that originates in white blood cells in the skin. Lymphoma is a type of cancer that develops in white blood cells called lymphocytes. Lymphocytes are an integral part of the body’s immune system. They are found in lymph nodes, which are small clusters of immune tissue located at various locations throughout the body, as well as in other areas of the body, such as the bone marrow, spleen, and other organs, including the skin.
https://treatcancer.com/wp-content/uploads/2015/12/cancer-cells-541954_640.jpg 416 640 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-11-30 23:13:042015-12-15 04:36:36Atezolizumab Shows Early Positive Data for Treating Metastatic Melanoma
A study released by Swiss pharmaceutical company Roche in November shows early positive data for new cancer drug atezolizumab, which was used in combination with another drug to treat advanced melanoma.
https://treatcancer.com/wp-content/uploads/2015/08/business_open-pharma_2.png 292 520 Jay Hansbrough https://treatcancer.com/wp-content/uploads/2015/08/SERO-logo-PNG-450x174.png Jay Hansbrough2015-08-16 01:57:072018-04-18 14:48:18FDA approves new skin cancer drug for basal cell carcinoma
The U.S. Food and Drug Administration (FDA) has approved a new skin cancer drug designed to treat basal cell carcinoma. The drug, Odomzo, will be used to treat locally advanced basal cell carcinomas in patients where the disease has returned after the original tumor was surgically removed. The drug will also be an option for patients who are not candidates for surgery or radiation treatment.